Effects of screening and systemic adjuvant therapy on ER-Specific US breast cancer mortality

Journal of the National Cancer Institute

Volumn 106, Issue 11, 2014, Pages

  Munoz, Diego ^a,b   Near, Aimee M ^c   Van Ravesteyn, Nicolien T ^d   Lee, Sandra J ^e   Schechter, Clyde B ^f   Alagoz, Oguzhan ^g   Berry, Donald A ⁱ   Burnside, Elizabeth S ^h   Chang, Yaojen ^c   Chisholm, Gary ⁱ   De Koning, Harry J ^d   Ergun, Mehmet Ali ^g   Heijnsdijk, Eveline A M ^d   Huang, Hui ^e   Stout, Natasha K ^e   Sprague, Brian L ^j   Trentham Dietz, Amy ^h   Mandelblatt, Jeanne S ^c   Plevritis, Sylvia K ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e HARVARD MEDICAL SCHOOL   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g University of Wisconsin Madison   (United States)

^h UNIVERSITY OF WISCONSIN   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j UNIVERSITY OF VERMONT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAMOXIFEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CANCER STAGING; CHEMISTRY; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; HEALTH SURVEY; MASS SCREENING; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURVIVOR; TRENDS; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; MORTALITY; NEOPLASM STAGING; POPULATION SURVEILLANCE; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVORS; UNITED STATES;

EID: 84985004003     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju289     Document Type: Article

References (48)

1. Kurian AW, Carlson RW. Chapter 17: Principles of Breast Cancer Therapy. In: Li CI, (ed). Breast Cancer Epidemiology: Springer; 2010:371-388.
2. Sedjo RL, Byers T, Barrera E Jr., et al. A midpoint assessment of the American Cancer Society challenge goal to decrease cancer incidence by 25% between 1992 and 2015. CA Cancer J Clin. 2007;57(6):326-340.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
4. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302(15):1685-1692.
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
6. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845-856.
7. Oakman C, Bessi S, Zafarana E, et al. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res. 2009;11(2):205.
8. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
9. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
10. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
11. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658-1667.
12. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
13. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367(21):1998-2005.
14. Kerlikowske K, Zhu W, Hubbard RA, et al. Outcomes of Screening Mammography by Frequency, Breast Density, and Postmenopausal Hormone Therapy. JAMA Intern Med. 2013;173(9):807-816
15. Jatoi I, Anderson WF, Jeong JH, et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29(17):2301-2304.
16. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-747.
17. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909-919.
18. Olsen O, Middleton P, Ezzo J, et al. Quality of Cochrane reviews: assessment of sample from 1998. BMJ. 2001;323(7317):829-832.
19. Kerlikowske K, Hubbard RA, Miglioretti DL, et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med. 2011;155(8):493-502.
20. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006;(36):30-6.
21. Clarke LD, Plevritis SK, Boer R, et al. A comparative review of CISNET breast models used to analyze U.S. breast cancer incidence and mortality trends. J Natl Cancer Inst Monogr. 2006;(36):96-105.
22. Fryback DG, Stout NK, Rosenberg MA, et al. The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monogr. 2006;(36):37-47.
23. Mandelblatt J, Schechter CB, Lawrence W, et al. The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr. 2006;(36):47-55.
24. Plevritis SK, Sigal BM, Salzman P, et al. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006;(36):86-95.
25. Tan SY, van Oortmarssen GJ, de Koning HJ, et al. The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr. 2006;(36):56-65.
26. Holford TR, Cronin KA, Mariotto AB, et al. Changing patterns in breast cancer incidence trends. J Natl Cancer Inst Monogr. 2006;(36):19-25.
27. Human Mortality Database. Berkeley: University of California, Berkeley. Available at: http://www.mortality.org. Accessed September 30, 2005.
28. Cronin KA, Yu B, Krapcho M, et al. Modeling the dissemination of mammography in the United States. Cancer Causes Control. 2005;16(6):701-712.
29. Mariotto AB, Feuer EJ, Harlan LC, et al. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006;(36):7-15.
30. Cronin KA, Mariotto AB, Clarke LD, et al. Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality. J Natl Cancer Inst Monogr. 2006;(36):26-29.
31. Mariotto A, Feuer EJ, Harlan LC, et al. Trends in use of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst. 2002;94(21):1626-1634.
32. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352(9132):930-942.
33. Fowble BL, Schultz DJ, Overmoyer B, et al. The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys. 1994;30(1):23-33.
34. Jayasinghe UW, Taylor R, Boyages J. Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg. 2005;75(9):762-767.
35. Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009;11(4):R59.
36. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242-1255.
37. Kurian AW, Munoz DF, Rust P, et al. Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. J Clin Oncol. 2012;30(5):497-506.
38. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222-231.
39. Bonomi AE, Boudreau DM, Fishman PA, et al. Quality of life valuations of mammography screening. Qual Life Res. 2008;17(5):801-814.
40. El-Tamer MB, Ward BM, Schifftner T, et al. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg. 2007;245(5):665-671.
41. van Ravesteyn NT, Miglioretti DL, Stout NK, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med. 2012;156(9):609-617.
42. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. Two years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897): 1021-1028.
43. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
44. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
45. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
46. Amer Soc Clinical Oncology. Available at: http://www.asco.org/guidelines/breast-cancer. Accessed October 08, 2013.
47. Chlebowski RT, Anderson GL. The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. J Natl Cancer Inst. 2011;103(4):284-285.
48. Farhat GN, Parimi N, Chlebowski RT, et al. Sex Hormone Levels and Risk of Breast Cancer With Estrogen Plus Progestin. J Natl Cancer Inst. 2013;105(19):1496-1503.